Clinical Trials
5 trialsNCT06239220 2026-02-27
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT01385423 2025-07-24
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT05304754 2025-04-06
PHINK
Instituto de Investigación Hospital Universitario La Paz
Phase 1/2 Active not recruiting
NCT02395822 2018-02-20
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
Masonic Cancer Center, University of Minnesota
Phase 2 Completed